Article

Searching for HAdV-52, the putative gastroenteritis-associated human adenovirus serotype in Southern Hungary.

Regional Laboratory of Virology, Baranya County Institute of State Public Health Service, Pécs, Hungary.
The new microbiologica: official journal of the Italian Society for Medical, Odontoiatric, and Clinical Microbiology (SIMMOC) (impact factor: 1). 05/2009; 32(2):185-8. pp.185-8
Source: PubMed

ABSTRACT Human adenovirus (HAdV) serotype 52 has recently been discovered in the United States in samples from human patients with gastroenteritis of unknown etiology and is suspected to be a new human enteric pathogen. The aim of the present pilot study was to investigate whether this virus is circulating in the population of Southern Hungary by screening stool specimens collected from gastroenteritis cases and communal sewage samples in the area of Baranya County. A total of 209 diarrheic stool (124 from children and 85 from adults) and 45 influent sewage samples were screened for HAdV-52 by PCR using a primer pair specific to the gene of 12.5K protein in the E3 genomic region. The novel human adenovirus was not detected in any of the tested samples, suggesting that HAdV-52 was not circulating in the target population and the area during the study period. Since temporal and geographical fluctuations may markedly affect the epidemiology of human enteric pathogens, additional investigations are required to gain more in-depth insights into the ecology of this novel adenovirus.

0 0
 · 
0 Bookmarks
 · 
36 Views
  • Source
    Article: An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Running title: Lassa vaccine in SIV-positive macaques.
    [show abstract] [hide abstract]
    ABSTRACT: BACKGROUND: Lassa hemorrhagic fever (LHF) is a rodent-borne viral disease that can be fatal for human beings. In this study, an attenuated Lassa vaccine candidate, ML29, was tested in SIV-infected rhesus macaques for its ability to elicit immune responses without instigating signs pathognomonic for arenavirus disease. ML29 is a reassortant between Lassa and Mopeia viruses that causes a transient infection in non-human primates and confers sterilizing protection from lethal Lassa viral challenge. However, since the LHF endemic area of West Africa also has high HIV seroprevalence, it is important to determine whether vaccination could be safe in the context of HIV infection. RESULTS: SIV-infected and uninfected rhesus macaques were vaccinated with the ML29 virus and monitored for specific humoral and cellular immune responses, as well as for classical and non-classical signs of arenavirus disease. Classical disease signs included viremia, rash, respiratory distress, malaise, high liver enzyme levels, and virus invasion of the central nervous system. Non-classical signs, derived from profiling the blood transcriptome of virulent and non-virulent arenavirus infections, included increased expression of interferon-stimulated genes (ISG) and decreased expression of COX2, IL-1beta, coagulation intermediates and nuclear receptors needed for stress signaling. All vaccinated monkeys showed ML29-specific antibody responses and ML29-specific cell-mediated immunity. CONCLUSION: SIV-infected and uninfected rhesus macaques responded similarly to ML29 vaccination, and none developed chronic arenavirus infection. Importantly, none of the macaques developed signs, classical or non-classical, of arenavirus disease.
    Virology Journal 02/2013; 10(1):52. · 2.34 Impact Factor

Full-text

View
0 Downloads
Available from

Keywords

45 influent sewage samples
 
children
 
communal sewage samples
 
E3 genomic region
 
gastroenteritis
 
gastroenteritis cases
 
geographical fluctuations
 
HAdV
 
Human adenovirus
 
human enteric pathogens
 
in-depth insights
 
novel adenovirus
 
novel human adenovirus
 
present pilot study
 
primer pair specific
 
Southern Hungary
 
study period
 
target population
 
United States